| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Autobiography |
| Article Title |
Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tatsuya Fujino, Yoko Aoyagi, Mariko Takahashi, Ryoko Yada, Naoko Yamamoto, Yuki Ohishi, Akihiko Nishiura, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuizumi, Manabu Nakashima, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta and Munechika Enjoji |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Clinical Research from the National Hospital Organization of Japan |
|
| Ministry of Health, Labor and Welfare of Japan |
|
|
| Corresponding Author |
Munechika Enjoji, MD, PhD, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. enjoji@adm.fukuoka-u.ac.jp |
| Key Words |
Chronic hepatitis C; Interleukin 28B; Inosine triphosphatase; Peginterferon; Ribavirin |
| Core Tip |
Inosine triphosphatase (ITPA) polymorphism at rs1127354 is significantly associated with hemoglobin decline and reduction of ribavirin (RBV) during peginterferon-α + RBV therapy. However, the effect of the ITPA gene single-nucleotide polymorphism on treatment outcome is still unclear. In this study, ITPA CC genotype (rs1127354) was not inferior to CA/AA genotype for sustained virological response rates although CC genotype was a disadvantageous factor for the treatment in relation to completion rates and RBV dose. When full-length treatment is accomplished, the SVR rate tended to be higher in patients with the CC genotype, especially in a subset of patients with the favorable TT genotype (rs8099917) of Interleukin 28B. |
| Publish Date |
2013-08-01 15:35 |
| Citation |
Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of ITPA polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy. World J Gastrointest Pharmacol Ther 2013; 4(3): 54-60 |
| URL |
http://www.wjgnet.com/2150-5349/full/v4/i3/54.htm |
| DOI |
http://dx.doi.org/10.4292/wjgpt.v4.i3.54 |
